- Home
- QLYS vs ACLX Comparison
QLYS vs ACLX Comparison
Compare QLYS & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLYS
- ACLX
- Stock Information
- Founded
- QLYS 1999
- ACLX 2015
- Country
- QLYS United States
- ACLX United States
- Employees
- QLYS N/A
- ACLX N/A
- Industry
- QLYS Computer Software: Prepackaged Software
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- QLYS Technology
- ACLX Health Care
- Exchange
- QLYS Nasdaq
- ACLX Nasdaq
- Market Cap
- QLYS 4.5B
- ACLX 5.3B
- IPO Year
- QLYS 2012
- ACLX 2022
- Fundamental
- Price
- QLYS $150.32
- ACLX $87.50
- Analyst Decision
- QLYS Hold
- ACLX Strong Buy
- Analyst Count
- QLYS 18
- ACLX 14
- Target Price
- QLYS $154.19
- ACLX $103.67
- AVG Volume (30 Days)
- QLYS 639.2K
- ACLX 645.0K
- Earning Date
- QLYS 11-05-2024
- ACLX 11-07-2024
- Dividend Yield
- QLYS N/A
- ACLX N/A
- EPS Growth
- QLYS 22.85
- ACLX N/A
- EPS
- QLYS 4.53
- ACLX N/A
- Revenue
- QLYS $592,950,000.00
- ACLX $155,818,000.00
- Revenue This Year
- QLYS $11.15
- ACLX $20.54
- Revenue Next Year
- QLYS $7.65
- ACLX N/A
- P/E Ratio
- QLYS $32.41
- ACLX N/A
- Revenue Growth
- QLYS 9.66
- ACLX 230.33
- 52 Week Low
- QLYS $119.17
- ACLX $46.42
- 52 Week High
- QLYS $206.35
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- QLYS 60.88
- ACLX 47.47
- Support Level
- QLYS $140.31
- ACLX $83.69
- Resistance Level
- QLYS $155.93
- ACLX $107.37
- Average True Range (ATR)
- QLYS 5.62
- ACLX 5.90
- MACD
- QLYS -0.14
- ACLX -1.40
- Stochastic Oscillator
- QLYS 55.69
- ACLX 37.57
About QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.